Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Investor Presentation (January 2025)
29 slides from Legend Biotech's investor presentation, Jan 14, 2025
Slide 1: Legend Biotech Corporate Presentation
1 Legend Biotech CORPORATE PRESENTATION JANUARY 14, 2025
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in
Slide 3: Legend Biotech – Transforming Cancer Care
3 1. As of September 30, 2024 11 Pipeline Programs in Hematologic Malignancies, Solid Tumors, and Autoimmune Diseases Legend Biotech – Transforming Cancer Care Pioneer and Leader in CAR - T Therapy Revolution 2,500+ Employees 450+ Focused on R&D Stand - alone with End - to - end Capabilities Partner
Slide 4: CARVYKTI Proven Leader on the Path to Cure
4 CARVYKTI ® Proven Leader on the Path to Cure First and only CAR - T cell therapy providing superior OS vs SoC in Multiple Myeloma >4,500 treated patients treated Significant sales growth trajectory, strong 2L+ launch with the OS benefit achieved Strongest CAR - T launch to date, with $286M in net
Slide 5: Multiple Myeloma Blood Cancer with a High Unmet Need
CI, confidence interval; PI, Proteasome Inhibitor; IMiD, immunomodulatory drug; MM, multiple myeloma; OS, overall survival 1. Globocan 2022 World Fact Sheet: https://gco.iarc.who.int/media/globocan/factsheets/cancers/35 - multiple - myeloma - fact - sheet.pdf. Accessed March 2024. 2. Globocan 2022 W
Slide 6: Legend and J&J Global Collaboration
6 Legend and J&J Global Collaboration Worldwide Collaboration and License Agreement to Develop and Commercialize Cilta - cel with J&J, the #1 Global Multiple Myeloma Market Leader 50/50 United States Europe 50/50 Japan 50/50 Working Together to Realize CARVYKTI’S $5B+ Potential
Slide 7: CARVYKTI - First in MM to Achieve OS Benefit vs SOC
7 CARVYKTI ® - First CAR - T in MM to Achieve OS Benefit vs SOC Gold Standard for Oncology Trials • One - time infusion significantly prolonged overall survival and improved quality of life 1 • 45% reduction in risk of death with CARVYKTI ® vs SOC in patients w i th lenalidomide - refractory MM afte
Slide 8: Maximizing Our CARVYKTI Market Leadership
8 MAXIMIZING OUR CARVYKTI MARKET LEADERSHIP
Slide 9: A New Standard for Launches
9 Data Source: Companies' public filings. A New Standard for CAR - T Launches CARVYKTI ® - I NDUSTRY LEADI NG EARLY LAUNCH PERFO RMANCE FI RST TEN Q UARTERS O UTPERFO RMI NG HI STO RI CAL CAR - T LAUNCHES Quarterly sales ($MM) 286 102 387 98 224 124 450 400 350 300 250 200 150 100 50 0 Q1 Q2 Q3 Q4 Q
Slide 10: CARVYKTI Uptake Continues
10 CARVYKTI ® Uptake Continues Continued Market Penetration and Earlier Lines of Treatment Represents Significant Opportunity for Continued Growth QoQ Growth 2 YoY Growth 1 54% 84% U.S. 35% 125% OUS 53% 88% Global 24 55 55 70 114 140 146 140 167 258 0 0 0 2 3 12 13 16 20 27 0 50 100 150 200 250 CARV
Slide 11: Earlier Line Studies Another Opportunity to Change the Treatment Paradigm
ASCT, autologous stem cell transplant; DVRd, daratumumab, bortezomib, lenalidomide, dexamethasone; NDMM, newly diagnosed multiple myeloma; VRd, bortezomib, lenalidomide, dexamethasone. 1. Clinicaltrials.gov: NCT04133636. 2. Clinicaltrials.gov: NCT04923893. 3. Clinicaltrials.gov: NCT05257083. CARTITU
Slide 12: Unlocking the Blockbuster Global Market Opportunity
12 Unlocking the Blockbuster Global Market Opportunity MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR CAR - T THERAPY Frontline : ~52k patients 2L to 4L: ~80k patients 5L+ : ~22k patients 1. MHLW is the Ministry of Health, Labour and Welfare in Japan. 2. NMPA is the National Medical Products Administration
Slide 13: Outpatient Administration: Key Competitive Advantage
13 Outpatient Administration: Key Competitive Advantage • Extensive use of CARVYKTI in outpatient setting is a key differentiator - Unique delayed CRS 1 onset allows for outpatient administration options to best serve patient needs • Patients and caregivers prefer to return home after treatment • Su
Slide 14: Global Manufacturing Footprint
14 Global Manufacturing Footprint Raritan, NJ US / EU / JP / ROW Launch/ Commercial Site for CARVYKTI ® x GMP Operational • Approval of new Raritan section expected in 2H25 Morris Plains, NJ Novartis CMO Site x Clinical production started July 2024 • Commercial production expected in 1H 2025 Expandi
Slide 15: US and EU CARVYKTI Supply Overview
15 US and EU CARVYKTI ® Supply Overview 1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26 2H26 1H27 2H27 2028 2029 2030 Launch Facilities Expansion/ Process Optimization Raritan Slot Ramp Up Obelisc Clinical + Commercial Online Tech Lane Online CMO Online Raritan Physical Expansion Facilities Driving To
Slide 16: Building Upon CARVYKTI's Leadership Position
16 1. ATC – Authorized treatment center Building Upon ‘s Leadership Position 2022 2023 Indication Expansion Deepening Community Penetration Preparing for 1L Use Data Generation in Support of CARVYKTI ® Redefining Treatment Expectations in MM 4L+ Approval 2L+ Approval Continued Market Leadership 2026
Slide 17: Building Next Generation Programs
17 BUILDING NEXT GENERATION CAR - T PROGRAMS
Slide 18: Pipeline
18 *I n collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. † Phase 1 investigator - initiated trial in China. ‡ IND applications have been cleared by the U.S. FDA. # Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/o
Slide 19: Our Differentiated R&D Approach
19 Our Differentiated R&D Approach Potential best - in - class proprietary technology platforms and end - to - end capability Armoring strategy for solid tumors Multiple armored CAR - T strategies to overcome challenges in treatment of solid tumors Diverse platform for allogeneic treatments Diverse
Slide 20: Legend and Novartis Collaboration
20 Legend and Novartis Collaboration Legend and Novartis have an exclusive, global license agreement to advance certain DLL3 - targeted CAR - T therapies, including LB2102, an investigational therapy for small cell lung cancer.
Slide 21: Small Cell Lung Cancer A Large Unmet Medical Need
21 Small Cell Lung Cancer A Large Unmet Medical Need US: Incidence is ~35,000 1 Lung Cancer is the Second Most Diagnosed Cancer in the US 1 And the leading cause of cancer death in both men and women, accounting for ~ 20 % of all cancer deaths 1 and in 2 out of 3 people with SCLC have extensive stag
Slide 22: LB2102: Legend Armored Targeting DLL3 For Small Cell Lung Cancer
22 LB2102: Legend Armored CAR - T Targeting DLL - 3 For Small Cell Lung Cancer TARGET • DLL - 3, a promising target with prevalent & homogeneous expression in SCLC (~80% positive) and other neuroendocrine tumors • Minimal to no expression in normal tissues MoA/Scientific Rationale • Tandem humanized
Slide 23: LB1908: Legend Targeting CLDN18.2
23 LB1908 (LCAR - C18S): Legend CAR - T Targeting CLDN18.2 For gastric cancer, esophageal cancer and pancreatic cancer TARGET • Claudins (CLDN) are a family of tight junction proteins 1 - CLDN18.2 is expressed in gastric cancer and pancreatic cancer 2 MoA/Scientific Rationale • LB1908 targets CLDN 1
Slide 24: Upcoming Anticipated Legend Milestones
24 * Novartis Pharmaceuticals Corporation Upcoming Anticipated Legend Milestones COMMERCIAL • Increasing demand and deepening penetration into the community • Outpatient program expansion • OS label update CLINICAL • Topline data in CART - 5 • Advance pipeline programs, advance two programs into IND
Slide 25: Legend Biotech is the proven leader forging the path to cure
25 is the proven leader forging the path to cure.
Slide 26: Thank You
BIOTECH THANK YOU
Slide 27: Appendix
eIOTECH APPENDIX
Slide 28: Parkinsonism Incidence Decreased to <1% in CARTITUDE-4
28 Parkinsonism Incidence Decreased to <1% in CARTITUDE - 4 CARTITUDE - 1 • 5 cases of Parkinsonism (5%) with median 12.4 months of follow up (ASH 2020) • In the label, CARTITUDE - 1: 6% (4% Grade 3/4) (n=97) CARTITUDE - 4 • 1 case of Parkinsonism ( 0.6% , Grade 1) with median 15.9 months follow up
Slide 29: Competitive Landscape in RRMM Treatment
Competitive Landscape in RRMM Treatment Trial Comparator PFS (months) PFS HR OS (months) OS HR 0.55 NR vs NR 0.29 NR vs 11.8 PVd or DPd CARTITUDE - 4 Carvykti 1.01 41.1 vs 37.9 0.49 13.8 vs 4.8 SoC KarMMa - 3 1 Abecma 0.94 35.6 vs 31.6 0.56 11.7 vs 6.9 Vd OPTIMISMM 2 PVd 0.82 34.4 vs 23.7 0.66 9.9 v
Legend Biotech — Investor Presentation (January 2025) on 6ix